Alterations in integrin expression modulates invasion of pancreatic cancer cells
© Walsh et al. 2009
Received: 4 August 2009
Accepted: 13 October 2009
Published: 13 October 2009
Factors mediating the invasion of pancreatic cancer cells through the extracellular matrix (ECM) are not fully understood.
In this study, sub-populations of the human pancreatic cancer cell line, MiaPaCa-2 were established which displayed differences in invasion, adhesion, anoikis, anchorage-independent growth and integrin expression.
Clone #3 displayed higher invasion with less adhesion, while Clone #8 was less invasive with increased adhesion to ECM proteins compared to MiaPaCa-2. Clone #8 was more sensitive to anoikis than Clone #3 and MiaPaCa-2, and displayed low colony-forming efficiency in an anchorage-independent growth assay. Integrins beta 1, alpha 5 and alpha 6 were over-expressed in Clone #8. Using small interfering RNA (siRNA), integrin β1 knockdown in Clone #8 cells increased invasion through matrigel and fibronectin, increased motility, decreased adhesion and anoikis. Integrin alpha 5 and alpha 6 knockdown also resulted in increased motility, invasion through matrigel and decreased adhesion.
Our results suggest that altered expression of integrins interacting with different extracellular matrixes may play a significant role in suppressing the aggressive invasive phenotype. Analysis of these clonal populations of MiaPaCa-2 provides a model for investigations into the invasive properties of pancreatic carcinoma.
Pancreatic cancer is a devastating disease; it is the eighth most common cause of death (from cancer in both sexes combined) in the World, and is responsible for 227,000 deaths per year . The median survival time after tumour detection is 3-6 months , with an all-stage 5-year survival rate of < 5% . Surgery offers the best possibility for survival but at time of diagnosis, only 15% of patients are eligible for resection . The poor outcome is mainly due to difficulties in early detection, lack of an effective treatment and limited understanding of the biological characteristics of this disease. Intrinsic resistance to chemotherapy and radiation  coupled with its early systematic dissemination, local tumour progression and metastatic propensity are associated with pancreatic cancer .
The processes involved in tumour cell invasion and metastasis are complex. The ability of cancer cells to degrade and adhere to the basement membrane and metastasise to distant organs is one of the most critical aspects of cancer. Adhesion molecules, such as integrins mediate direct cell-cell recognition and cell-matrix interactions  are essential for tumour cell migration  and for basement membrane penetration . In pancreatic cancer, expression of integrins α6β1 [10–12] and αvβ3  have previously been associated with invasion in cell lines and tissues. However, contrasting results with respect to tumour type and integrin expression patterns makes it difficult to draw general conclusions on the role of specific integrins. Tumour progression and metastasis are associated with changes in a multitude of integrin signalling cascades. Transformed cancer cells are often characterised by the loss/reduction of integrin expression [14, 15]. Extracellular matrix (ECM)-ligand binding to an integrin initiates signals, which are transmitted via different, yet interconnecting, pathways and elicit various cell functions, such as morphological changes, adhesion, migration and gene activation, all relevant to the metastatic cascade. The surrounding microenvironment and adhesion properties of pancreatic tumours and sub-populations within the tumour may determine which integrins increase or reduce metastasis in particular tumours . Advanced tumours often contain a variety of sub-populations, which have differing metastatic potential . Li et al.  identified a highly tumourigenic sub-population of pancreatic cancer cells expressing the cell surface markers CD44, CD24, and epithelial-specific antigen (ESA) capable of self-renewal and increased tumourigenic potential. The identification of pancreatic cancer stem cells has many significant implications for the treatment of pancreatic cancer.
Therefore, in this study, we isolated clonal isogenic sub-populations, derived from the original pancreatic cancer cell line, MiaPaCa-2. Clone #3 and Clone #8 exhibit identical genetic fingerprints with different malignancy-related phenotypes. We examine how altered integrin expression including β1, α5 and α6 affects invasion, motility, adhesion and anoikis using RNAi. Furthermore, the role of integrins in the aggressive invasive phenotype, which correlates with in vitro malignant transformation in this pancreatic cancer cell line model, could help to define an invasion/metastatic-related model for pancreatic cancer.
The human pancreatic cell line MiaPaCa-2 was obtained from the European Collection and Cell Cultures (ECACC, UK). Clone #3 and Clone #8 were obtained by limitation dilution cloning in this laboratory, adapted from . The parental cell line was diluted to a concentration of 3 cells/ml and 100 μl plated onto each well of a 96-well plate. After 24 hours each well was studied for single cells, which were allowed to grow into colonies. Once confluence was achieved, cells were transferred to a T25-T75 cm3 flask within 2 weeks. The colonies were then screened by invasion assay to assess their invasive abilities. Cells were maintained in a humidified atmosphere containing 5% CO2 at 37°C in Dulbecco's modified Eagles medium (DMEM) supplemented with 5% foetal bovine serum (Sigma-Aldrich). Antibiotics were not used in the growth media. All cell lines were free from Mycoplasma as tested with the indirect Hoechst staining method.
Invasion and Motility assays
Invasion assays were performed using an adapted method . Matrigel was diluted to 1 mg/ml in serum free DMEM. Laminin, fibronectin and collagen type IV was diluted to 25 μg/ml in PBS and collagen type I to 10 μg/ml. 100 μl of ECM protein was placed into each insert (Falcon) (8.0 μm pore size), in a 24-well plate (Costar). The ECM coated inserts were incubated overnight at 4°C. The following day, the ECM was allowed polymerise at 37°C for 1 hr. The inserts were then washed with serum-free DMEM, 100 μl of complete DMEM was added to the wells and 1 × 105/100 μl cells were then seeded onto the insert. 500 μl of complete DMEM was added into the underside of the well. After 24 hours incubation, the inside of the insert was wiped with a wet cotton swab. The under surface was gently rinsed with PBS and stained with 0.25% crystal violet for 10 minutes, rinsed again with sterile water and allowed to dry. To determine total number of invading cells, the inserts were then viewed under the microscope and the number of cells/field in 10 random fields were counted at 200× magnification. The average number of cells/field was then multiplied by a factor of 140 (growth area of membrane/field area viewed at 200× magnification (calibrated using a microscope graticule)). The mean values were obtained from a minimum of three individual experiments and were subjected to t -tests and ANOVA. Motility assays were carried out in the same manner as invasion assays without the addition of ECM on the insert. Experiments were performed in triplicate.
Adhesion assays were performed using a modified method . 24-well plates were coated with 250 μl of 25 μg/ml ECM proteins (laminin, fibronectin and collagen type IV), 10 μg/ml of collagen type I and 1 mg/ml of matrigel. ECM proteins were incubated overnight at 4°C. To reduce non-specific binding, 0.5 ml of 0.1% BSA-PBS solution was added to each well and incubated for 20 minutes, then rinsed twice with sterile PBS. A single cell suspension was obtained, 1 ml of a 2.5 × 104 cell suspension was added onto the pre-coated 24-well plates in triplicate and allowed to attach for 60 minutes. Blank wells contained ECM proteins but no cells; controls were uncoated wells with cells. After 60 minutes, the non-adhered cells were removed by washing twice with sterile PBS. 200 μl of freshly prepared phosphatase substrate (10 mM p -nitrophenol phosphate in 0.1 M sodium acetate, 0.1% Triton X-100 pH 5.5) was added to each well. Plates were then incubated in the dark at 37°C for 2 hours. The enzymatic reaction was stopped by the addition of 100 μl 1 M NaOH. The absorbance was read on a BIO-TEK plate reader at 405 nm with a reference wavelength of 620 nm.
24-well plates were coated with 200 μl of poly-2-hydroxyethyl methacrylate (poly-HEMA, 12 mg/ml dissolved in 95% ethanol, Sigma) and allowed to dry overnight. 1 ml of a single cell suspension of 1 × 105cells was plated onto standard 24 well plates or poly-HEMA coated plates. After 24 hours incubation at 37°C in a humidified atmosphere containing 5% CO2, the viability of cells was quantitatively measured using alamarBlue indicator dye (Serotec). The absorbance was read on a BIO-TEC plate reader at 570 nm with a reference wavelength of 600 nm.
Soft agar colony-forming assay
Soft agar assays or anchorage independent growth assays were carried out using a modified method . 1.548 g of agar (Bacto Difco, 214040) was dissolved in 100 ml of ultra pure water and autoclaved. This agar was then melted in a microwave oven immediately prior to use and incubated at 44°C. 50 ml of agar was then added to 2× DMEM AgarMedium (AgM), mixed well and quickly dispensed onto 35 mm sterile petri dishes. The plates were allowed to set at room temperature and the remaining AgM was returned to the water bath with the temperature reduced to 41°C. 10% FCS was added to the AgM. Cells were harvested and resuspended in medium without serum, ensuring that a single cell suspension was obtained. The cells were diluted to 2 × 104 cells/ml in a total of 5 ml. 5 ml of agar was then added to each suspension, mixed well and 1.5 ml was dispensed onto each pre-set agar plate, in triplicate, giving a final concentration of 1.5 × 104 cells per plate. The plates were placed on trays containing a small volume of water to prevent the agar from drying out. On day 0, cells were counted and subsequently cultured for an additional 10 days. After this time the colonies were counted using an inverted microscope at 400×. Ten areas were viewed per plate and the total number of colonies present was extrapolated and the percentage colony forming efficiency (CFE) was determined by expressing the number of colonies formed after 10 days as a percentage of the number of cells counted on day 0.
Whole protein was extracted from cell lysates using 1× lysis buffer (50 mM Tris-Cl, 150 mM NaCl, and 0.5% NP-40). Lysates were centrifuged for 10 min at 14,000 rpm at 4°C. Protein concentrations were determined using the Bio-Rad protein assay according to manufacturer's instructions (Bio-Rad). 35 μg of protein was separated by 7.5% SDS-PAGE under reducing conditions. Proteins were transferred to nitrocellulose membrane (Amersham). Membranes were blocked at 4°C overnight in TBS (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2.7 mM KCl) containing 5% (w/v) lowfat milk powder. Membranes were probed with specific antibodies. Anti-β1 (MAB1951Z-20), anti-α5 (AB1949) and anti-α6 (MAB1982) were obtained from Chemicon (Millipore, Europe). Beta-actin was used as loading control (Sigma, A5441). Membranes were washed 3× for 5 min with PBS-Tween-20 (0.1%) and incubated with secondary antibodies, anti-mouse and anti-rabbit (Sigma) for 1 hr at room temperature and washing step repeated. Protein bands were detected with Luminol reagent (Santa Cruz Biotechnology).
Integrin siRNA transfection
Two integrin β1 (ITGB1) target siRNAs (#109877, #109878 (validated) Ambion Inc.) were used to silence integrin β1 expression. Two integrin α5 (ITGA5) target siRNAs (#106728, #111113 Ambion Inc.) and two integrin α6 (ITGA6) target siRNAs (#8146, #103827 (validated) Ambion Inc.) were used to silence the respective target genes. Solutions of siRNA at a final concentration of 30 nM were prepared in OptiMEM (Gibco™). NeoFX solution was prepared in OptiMEM and incubated at room temperature for 10 min. After incubation, an equal volume of neoFX solution was added to each siRNA solution, mixed well and incubated for a further 10 min. 100 μl of neoFX/OptiMEM solutions were added into a 6 well plate in duplicate. Clone #8 (3 × 105) cells were added onto the siRNA solution. The plates were gently mixed and incubated for 24 hours. The transfection mixture was removed and replaced with fresh medium. Positive control, kinesin (Ambion Inc.) was included in each triplicate experiment. Invasion, motility, adhesion and anoikis assays were then carried out 48 hours after transfection, as previously described.
Student's t-test was used for statistical analyses of invasion, motility, adhesion, anoikis and soft agar assays. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005 indicated statistical significance. Data are presented as mean ± standard deviation. Each experiment was repeated at least three times. Multiple group comparison experiments were validated by ANOVA.
Single cell cloning
Invasion and adhesion to ECM proteins
The more invasive Clone #3, displays significantly decreased adhesion to matrigel (p = 0.01), laminin (p = 0.02), fibronectin (p = 0.01) and collagen type IV (p = 0.01) compared to the parental cell line (Fig 2B). In contrast a significant increase in adhesion was observed to collagen type I (p = 0.003), although the level of adhesion to the collagens was significantly lower than that to fibronectin or laminin. The less invasive Clone #8, showed significantly increased adhesion to matrigel (p = 0.04) and laminin (p = 0.002). Adhesion to fibronectin and collagen type I were also increased, but not significantly and adhesion to collagen type IV was decreased significantly (p = 0.001) for Clone #8.
Anoikis and anchorage-independent growth
Integrin β1 knockdown
Integrin α5 and α6 knockdown
A slight decrease in adhesion to matrigel and laminin was observed although not significantly, while a significant reduction in adhesion to fibronectin was observed after integrin α5 siRNA treatment of Clone #8 cells (p = 0.02, p = 0.03), ANOVA (p = 0.02). Adhesion to matrigel and fibronectin was not altered with integrin α6 siRNA treatment; however adhesion to laminin was reduced (p = 0.08 and p = 0.01), ANOVA (p = 0.01) (Fig 6C). No significant change in anoikis response was observed after either integrin α5 and α6 siRNA transfection, compared to cells treated with scrambled control (Fig 6D).
One of the most lethal aspects of pancreatic cancer is its early systemic dissemination and tumour progression . The inability to diagnose pancreatic cancer at an early stage has contributed to poor prognosis, as well as the difficulties in treating the metastatic disease. The exact mechanism of pancreatic invasion and metastasis has not been fully elucidated and a better understanding of these processes is essential in treating this disease.
To study the inherent heterogeneity of differing sub-populations within a tumour, we isolated isogenic clonal populations from the human pancreatic cell line, MiaPaCa-2, by single cell cloning. Two sub-populations displaying differences in invasion were further analysed to characterise the in vitro invasive phenotype. Clone #3 was characterised as highly invasive and motile with decreased adhesion to ECM proteins. The less invasive Clone #8 displayed increased adhesion to ECM proteins. Neither clone showed an affinity to collagen type I and IV. Grzesiak et al.  previously determined that the parental cell line MiaPaCa-2 does not express collagen-binding integrins α1 and α2, but showed that the cells are metastatic in an orthotopic mouse model and preferentially migrate on laminin-1. Although collagen type IV constitutes the major intrinsic component of the extracellular matrix , the ability of the clonal populations in our study to invade or/adhere to matrigel could be due to laminin, another major component of the ECM, and to a lesser extent fibronectin, which represents a significant step in metastasis . Changes in adhesive characteristics, invasion and motility of cells have been suspected to play a role in mediating the spread of malignant cells.
Clone #3 displays the characteristics of an aggressive cancer, with decreased adhesion facilitating increased motility and invasion, coupled with the ability to survive and to form colonies in anchorage independent conditions. These features could be compared to the in vivo situation where the ability of tumour cells to detach from the primary tumour, invade through the ECM, survive in the blood stream, and invade and form tumours at secondary sites, leads to the formation of metastases. Therefore, we believe that Clone #3 represents an in vitro model of tumour cells with increased metastatic potential. In contrast Clone #8 appears to be a model of tumour cells with decreased metastatic potential, showing decreased invasion, increased adhesion, increased sensitivity to anoikis and reduced ability to grow and form colonies in anchorage-independent conditions.
Integrins are involved in regulating growth, differentiation, and death by regulating the interaction between cell and ECM . In pancreatic cancer, links have previously been established between increased invasion and decreased adhesion to ECM proteins in vitro and to high metastatic potential in vivo [27–29].
In general, the loss or gain of expression of individual integrins appears to be indirectly associated with malignant transformation and involved in tumour progression and metastasis. Over expression of α5β1 in CHO cells demonstrated reduced malignancy , whereas α2β1 and α3β1 were expressed in non-neoplastic and fibroadenomas but were low or absent in highly invasive mammary carcinomas . In our study, Clone #3 showed reduced expression of integrins β1, α5 and α6 compared to Clone #8, which correlates with the reduced adhesion to laminin and fibronectin, as integrin α5β1 is a receptor for fibronectin and α6β1 is a receptor for laminin [32, 26]. Integrin β1, α5 and α6 siRNA transfection in Clone #8 resulted in significantly increased motility and invasion through matrigel and fibronectin, and reduced adhesion to matrigel and fibronectin. Loss of integrin β1 did not alter the invasion or adhesion of Clone #8 cells to laminin, but loss of α6 significantly reduced adhesion to laminin. These results suggest that inhibition of integrin β1 alone is not sufficient to block adhesion to laminin. Other integrin complexes such as α6β4  could control laminin-mediated adhesion/invasion in these cells. Gilcrease et al.  showed that α6β4 cross linking in suspended non adherent breast cancer cells resulted in cell surface clustering of EGFR, increasing EGFR-mediated activation of Rho in response to EGF, which may lead to tumour cell migration. Knockdown of the expression of integrin β1 in Clone #8 also revealed a more anoikis resistant phenotype. Disruption of β1 integrin complexes has previously implicated in induction of anoikis [35–37]. These experiments support the hypothesis that decreased expression of these integrins β1, α5 and α6, in Clone #3 plays a role in the aggressive invasive phenotype observed in vitro. Reduced expression of integrin β1, but not α5 and α6, appears to play an important role in anoikis resistance in this model. Therefore, targeting of integrins specific to certain tumours may provide viable options for therapeutic treatment.
We have established that sub-populations within a pancreatic cancer cell line display varied invasion and adhesive interactions with ECM proteins. Low adhesion, high motility and invasion, reduced integrin α5, α6 and β1 expression, anoikis resistance and anchorage-independent growth in Clone #3 represents a highly invasive phenotype. This is the first study to report the relationship between invasion, adhesion, anoikis and anchorage independent colony formation within sub-populations of a pancreatic cancer cell line. In vivo analysis of these clonal populations of MiaPaCa-2 will be required to determine if the aggressive invasive phenotype in vitro correlates with increased metastatic potential in vivo. Further investigation of this aggressive phenotype may help to identify novel markers and targets for invasion and metastasis in pancreatic cancer.
This work was supported by the PRTL1 Cycle 3 and 4 programme of the Higher Education Authority.
- Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55: 74–108.View ArticlePubMed
- Spinelli GP, Zullo A, Romiti A, Di Seri M, Tomao F, Miele E, Spalletta B, Eramo A, Hassan C, Tomao S: Long-term survival in metastatic pancreatic cancer. A case report and review of the literature. JOP 2006, 7: 486–491.PubMed
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007, 57: 43–66.View ArticlePubMed
- Muller MW, Friess H, Koninger J, Martin D, Wente MN, Hinz U, Ceyhan GO, Blaha P, Kleeff J, Buchler MW: Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg 2008, 195: 221–228.View ArticlePubMed
- Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358: 1576–1585.View ArticlePubMed
- Yachida S, Iacobuzio-Donahue CA: The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med 2009, 133: 413–422.PubMed
- Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69: 11–25.View ArticlePubMed
- Holly SP, Larson MK, Parise LV: Multiple roles of integrins in cell motility. Exp Cell Res 2000, 261: 69–74.View ArticlePubMed
- Uhm JH, Gladson CL, Rao JS: The role of integrins in the malignant phenotype of gliomas. Front Biosci 1999, 4: D188–99.View ArticlePubMed
- Weinel RJ, Rosendahl A, Pinschmidt E, Kisker O, Simon B, Santoso S: The alpha 6-integrin receptor in pancreatic carcinoma. Gastroenterology 1995, 108: 523–532.View ArticlePubMed
- Vogelmann R, Kreuser ED, Adler G, Lutz MP: Integrin alpha6beta1 role in metastatic behavior of human pancreatic carcinoma cells. Int J Cancer 1999, 80: 791–795.View ArticlePubMed
- Sawai H, Funahashi H, Yamamoto M, Okada Y, Hayakawa T, Tanaka M, Takeyama H, Manabe T: Interleukin-1alpha enhances integrin alpha(6)beta(1) expression and metastatic capability of human pancreatic cancer. Oncology 2003, 65: 167–173.View ArticlePubMed
- Hosotani R, Kawaguchi M, Masui T, Koshiba T, Ida J, Fujimoto K, Wada M, Doi R, Imamura M: Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis. Pancreas 2002, 25: e30–5.View ArticlePubMed
- Pignatelli M, Hanby AM, Stamp GW: Low expression of beta 1, alpha 2 and alpha 3 subunits of VLA integrins in malignant mammary tumours. J Pathol 1991, 165: 25–32.View ArticlePubMed
- Zutter MM, Mazoujian G, Santoro SA: Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am J Pathol 1990, 137: 863–870.PubMed
- Brakebusch C, Wennerberg K, Krell HW, Weidle UH, Sallmyr A, Johansson S, Fassler R: Beta1 integrin promotes but is not essential for metastasis of ras-myc transformed fibroblasts. Oncogene 1999, 18: 3852–3861.View ArticlePubMed
- Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 1977, 197: 893–895.View ArticlePubMed
- Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM: Identification of Pancreatic Cancer Stem Cells. Can Res 2007, 67: 1030–1037.View Article
- Heenan M, O'Driscoll L, Cleary I, Connolly L, Clynes M: Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance. Int J Cancer 1998, 71: 907–915.View Article
- Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987, 47: 3239–3245.PubMed
- Carter WG, Wayner EA, Bouchard TS, Kaur P: The role of integrins alpha 2 beta 1 and alpha 3 beta 1 in cell-cell and cell-substrate adhesion of human epidermal cells. J Cell Biol 1990, 110: 1387–1404.View ArticlePubMed
- Carey BM, Dooley M, Weedle R, Clynes M: Production of autostimulatory growth factors by the human carcinoma line, RPMI 2650. In Vitro Cell Dev Biol 1993, 29A: 153–160.View ArticlePubMed
- Grzesiak JJ, Bouvet M: The alpha2beta1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines. Br J Cancer 2006, 94: 1311–1319.View ArticlePubMed
- DiMagno EP, Reber HA, Tempero MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterolgy 1999, 117: 1464–1484.View Article
- Tryggvason K, Hoyhtya M, Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987, 907: 191–217.PubMed
- Shaw LM, Chao C, Wewer UM, Mercurio AM: Function of the integrin alpha 6 beta 1 in metastatic breast carcinoma cells assessed by expression of a dominant-negative receptor. Cancer Res 1996, 56: 959–963.PubMed
- Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K, Hollingsworth MA: Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int J Cancer 2000, 88: 507–518.View ArticlePubMed
- Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE: Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery 2004, 135: 555–562.View ArticlePubMed
- Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE: CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 2004, 23: 465–473.View ArticlePubMed
- Cheresh DA: Strucural and biologic properties of integrin-mediated cell adhesion. Clin Lab Med 1992, 12: 217–236.PubMed
- Gui GP, Puddlefoot JR, Vinson GP, Wells CA, Carpenter R: In vitro regulation of human breast cancer cell adhesion and invasion via integrin receptors to the extracellular matrix. Br J Surg 1995, 82: 1192–1196.View ArticlePubMed
- Lefcort F, Venstrom K, McDonald JA, Reichardt LF: Regulation of expression of fibronectin and its receptor, alpha 5 beta 1, during development and regeneration of peripheral nerve. Development 1992, 116: 767–782.PubMed
- Belkin AM, Stepp MA: Integrins as receptors for laminins. Microsc Res Tech 2000, 51: 280–301.View ArticlePubMed
- Gilcrease MZ, Zhou X, Lu X, Woodward WA, Hall BE, Morrissey PJ: Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer. J Exp Clin Can Res 2009, 28: 67.View Article
- Plath T, Detjen K, Welzel M, von Marschall Z, Murphy D, Schirner M, Wiedenmann B, Rosewicz S: A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor. J Cell Biol 2000, 150: 1467–1478.View ArticlePubMed
- Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J, Muthuswamy SK, Brugge JS: Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003, 5: 733–740.View ArticlePubMed
- Strater J, Wedding U, Barth TF, Koretz K, Elsing C, Moller P: Rapid onset of apoptosis in vitro follows disruption of beta 1-integrin/matrix interactions in human colonic crypt cells. Gastroenterology 1996, 110: 1776–1784.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.